Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CRHBP | P24387 | 2/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2834475 | 0.75 | — | — | |
| SCHEMBL22447830 | 0.70 | IDO1 (0.35) | KDM4EL3MBTL1LMNA | |
| SCHEMBL16112511 | 0.70 | IDO1 (0.35) | KDM4EL3MBTL1LMNA | |
| SCHEMBL2297883 | 0.65 | — | — | |
| SCHEMBL812359 | 0.65 | — | — | |
| SCHEMBL22362231 | 0.64 | TTR (0.43) | KDM4ELMNACRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL21784922 | 0.64 | LMNA (0.48) | KDM4ELMNACRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL22362234 | 0.64 | TTR (0.43) | KDM4ELMNACRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL22421614 | 0.64 | TTR (0.43) | KDM4ELMNACRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL22362223 | 0.64 | TTR (0.43) | KDM4ELMNACRHBPCRHR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418203-B1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO CO LTD (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2418203-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2012-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | BMP2, BMP4, BMP6 | HSD11B1 840/4885KDM4E 1704/4885L3MBTL1 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.